Allist's core lung-cancer drug fails global trial, but buyback and dividends cushion
Core drug fails global Phase III trial Allist's main drug, furmonertinib, failed a global Phase III trial for a specific lung-cancer mutation. Since this drug is about 98.7% of Allist's revenue, the failure raises doubts about future growth and overseas milestone payments, pushing the stock down.
This is the biggest new negative event, directly threatening the company's main revenue source.
Buyback plan supports the stock Allist's chairman proposed buying back 100–200 million yuan of shares for employee incentives. Buybacks can lift the stock price by reducing shares outstanding and signaling management's confidence, offering a counterweight to the trial failure.
This is a new positive action that directly offsets the negative trial news.
Strong first-half profit and dividend Allist reported first-half net profit up 46.6% to 1.54 billion yuan and revenue up 39.9%. It also plans a cash dividend of 6 yuan per 10 shares (270 million yuan total). Strong earnings and cash returns support the stock.
These are new financial results and a dividend plan that show fundamental strength.
Procurement suspension report adds uncertainty A report said furmonertinib was suspended from procurement at a major hospital. Allist said it is verifying the claim. If true, it could hurt sales, but the company says operations are normal, so the impact is uncertain.
This is a new potential regulatory issue that could affect sales of the core drug.